First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects
Public ClinicalTrials.gov record NCT01261767. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo-controlled, Single and Multiple Dose, Dose-escalation Trial of Anti-IL-20 (109-0012) 100 mg/Vial in Psoriatic Subjects, Followed by an Expansion Phase
Study identification
- NCT ID
- NCT01261767
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 55 participants
Conditions and interventions
Conditions
Interventions
- anti-IL-20 Drug
- placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2008
- Primary completion
- Dec 31, 2010
- Completion
- Dec 31, 2010
- Last update posted
- Feb 8, 2017
2008 – 2011
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Birmingham | Alabama | 35294 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90036 | — |
| Novo Nordisk Investigational Site | Skokie | Illinois | 60077 | — |
| Novo Nordisk Investigational Site | Indianapolis | Indiana | 46256-4697 | — |
| Novo Nordisk Investigational Site | Baltimore | Maryland | 21225 | — |
| Novo Nordisk Investigational Site | Boston | Massachusetts | 02111-1526 | — |
| Novo Nordisk Investigational Site | St Louis | Missouri | 63117-1206 | — |
| Novo Nordisk Investigational Site | New Brunswick | New Jersey | 08903 | — |
| Novo Nordisk Investigational Site | New York | New York | 10010 | — |
| Novo Nordisk Investigational Site | New York | New York | 10029 | — |
| Novo Nordisk Investigational Site | Winston-Salem | North Carolina | 27157 | — |
| Novo Nordisk Investigational Site | Portland | Oregon | 97210-5102 | — |
| Novo Nordisk Investigational Site | Portland | Oregon | 97239-4501 | — |
| Novo Nordisk Investigational Site | Dallas | Texas | 75246 | — |
| Novo Nordisk Investigational Site | Salt Lake City | Utah | 84132-0002 | — |
| Novo Nordisk Investigational Site | Norfolk | Virginia | 23507-1970 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01261767, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2017 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01261767 live on ClinicalTrials.gov.